4 citations,
April 2020 in “JAAD case reports” JAK inhibitors help hair regrowth but not fully effective for androgenetic alopecia.
3 citations,
January 2015 in “Nasza Dermatologia Online” Some treatments for autoimmune hair loss work, but JAK inhibitors like tofacitinib are promising for regrowth.
2 citations,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
1 citations,
October 2020 in “Journal of Investigative Dermatology Symposium Proceedings” The summit concluded that new treatments like Jak inhibitors show promise for Alopecia Areata and personalized approaches are needed.
1 citations,
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” Treating alopecia areata is difficult due to limited approved treatments, but new therapies like JAK inhibitors show promise.
1 citations,
November 2017 in “Dermatologic therapy” JAK inhibitors show promise as a future treatment for hair loss.
1 citations,
November 2016 in “Saengmyeong gwahag hoeji/Saengmyeong gwahak hoeji” New treatments for the autoimmune hair loss condition alopecia areata may include JAK inhibitors and other immunomodulators.
December 2024 in “Journal of Clinical Medicine of Kazakhstan” Vitiligo treatments include JAK inhibitors, UVB phototherapy, and dietary changes, with emotional support being important.
December 2024 in “International Journal of Dermatology” JAK inhibitors may help treat both alopecia areata and vitiligo, but more research is needed.
Topical treatments like minoxidil and corticosteroids are effective for hair loss, with JAK inhibitors promising for alopecia areata.
December 2024 in “Dermatological Reviews” New treatments for Alopecia Areata, like JAK inhibitors, are effective, and future research is exploring advanced therapies.
April 2024 in “Expert opinion on investigational drugs” JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.
March 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” New treatments for severe alopecia areata, especially JAK inhibitors, are recommended as first-line therapy.
January 2024 in “Pediatric rheumatology online journal” Early genetic testing and JAK inhibitors can help treat systemic inflammation in SAVI patients.
August 2023 in “JAAD international” Pediatric dermatologists have varied preferences for treating alopecia areata in children, with no standard FDA-approved treatments and some using JAK inhibitors despite risks.
July 2023 in “The Egyptian Journal of Hospital Medicine ” Alopecia areata is a hair loss condition caused by immune factors and can be treated with JAK inhibitors.
June 2023 in “Fundamental & clinical pharmacology” JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
May 2023 in “Journal of managed care & specialty pharmacy” Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.
April 2023 in “Revista colombiana de reumatología” JAK inhibitors like tofacitinib can effectively treat severe alopecia areata.
Alopecia Areata has no cure, treatments are limited, and the condition often recurs, but new therapies like JAK inhibitors show promise.
New treatments for alopecia areata, like JAK inhibitors and immunomodulators, are promising.
February 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors may help treat alopecia areata by reversing hair loss.
June 2024 in “Bőrgyógyászati és Venerológiai Szemle” New treatments for hair loss, like JAK inhibitors, PRP, anti-androgens, and minoxidil, offer better options.
185 citations,
June 2014 in “Journal of Investigative Dermatology” A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
157 citations,
December 2015 in “Journal of the American Academy of Dermatology” A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
130 citations,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
99 citations,
July 2017 in “Clinical Reviews in Allergy & Immunology” New treatments for Alopecia Areata show promise but need to be more effective and affordable.
96 citations,
December 2015 in “JAMA dermatology” Topical Ruxolitinib may safely treat severe hair loss.
79 citations,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
49 citations,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.